ALLO Stock Posts

$ALLO Earnings August 12 AMC. 21-Aug-26 Straddle Implies ±10.6% Move vs Prev. Move -8.2%

Allogene Therapeutics will report earnings after the market closes. View Calendar The market is expecting a ±13.1% move after earnings are reported. The average move for the past 4 quarters of earnings has been ±6.6%. View Expected Move (Conf Call: Aug 12 5:00 PM)

Allogene Therapeutics will report earnings after the market closes. View Calendar The market is expecting a ±9.2% move after earnings are reported. The average move for the past 4 quarters of earnings has been ±8.4%. View Expected Move (Conf Call: May 13 5:00 PM)

$ALLO Earnings May 13 AMC. 15-May-26 Straddle Implies ±9.2% Move vs Prev. Move -2.8%

Allogene Therapeutics trades 3,194 contracts. The company has the following event: Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) between Apr 1, 2026 and Jun 30, 2026. News: Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026